Pharma merger promises sweeping IP shake-up

In-house counsel at merging pharma businesses Wyeth and Pfizer face an uncertain future when the new entity looks to slash costs and increase efficiency. But, as WTR has discovered, the drugs companies have other problems to consider: from opportunistic counterfeiting to merging two very different IP teams.

Get unlimited access to all WTR content